The compassionate-use data provides strong proof-of-concept for QRX003 in Netherton Syndrome, but the single-patient nature limits generalizability. The key catalyst is the Phase 2/3 topline data expected in Q2 2027 — monitor for any updates on recruitment completion or early efficacy signals before that.
Price Chart
Executive Summary
Quoin Pharmaceuticals announced the publication of a peer-reviewed paper in Dermatology and Therapy detailing a pediatric compassionate-use case of QRX003 for Netherton Syndrome. The case report showed the patient's skin cleared from severe (IGA 4) to clear (IGA 0) over 21 months with no treatment-related adverse events. The filing also reiterates that full recruitment in the ongoing Phase 2/3 study (CL-QRX003-004) is expected by end of 2026, with topline data in Q2 2027.
Key Facts
- Peer-reviewed paper published in Dermatology and Therapy on October 13, 2026, introducing QRX003 and a pediatric compassionate-use case report.
- Pediatric patient's IGA improved from 4 (severe) at baseline to 1 (almost clear) at 6 weeks, then to 0 (clear) by 8 months, sustained over 21 months.
- Worst Itch Numeric Rating Scale (WI-NRS) reduced from 5 to 1 at 6 weeks and to 0 by 8 months.
- Patient discontinued antihistamines, glucocorticoids, antivirals, and has not required antibiotics since whole-body application began.
- No treatment-related adverse events reported.
- Phase 2/3 study CL-QRX003-004 interim results: 4 of 6 (66.7%) achieved primary endpoint (p=0.0087 vs. pre-specified alpha of 0.0215).
- Full recruitment of 20 participants expected by end of 2026; topline data expected in Q2 2027.
Financial Impact
No financial figures disclosed in the filing. The company is a pre-revenue clinical-stage biotech; the event is a clinical/regulatory catalyst, not a financial disclosure.
Risk Factors
- Single-patient compassionate-use data is not a substitute for controlled clinical trial results.
- Phase 2/3 study (CL-QRX003-004) has only 20 participants; small sample size increases risk of failure to replicate.
- No approved therapies exist for Netherton Syndrome — regulatory path is uncertain despite Orphan Drug and Fast Track designations.
- Company is pre-revenue with no disclosed cash runway — financing risk exists.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-117080 |
| Document: tm2627720d1_ex99-1.htm | 0001104659-26-117080 |
| Document: 0001104659-26-117080-index-headers.html | 0001104659-26-117080 |
| Document: 0001104659-26-117080-index.html | 0001104659-26-117080 |
| Document: 0001104659-26-117080.txt | 0001104659-26-117080 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $4.04 $3.99 | ▼ −1.24% | ▼ −1.76% | $4.01 (−0.74%) |
Oct 19, 2026 7d ago | ANALYST-UPGRADE | $3.98 $4.04 | ▲ +1.51% | ▲ +1.17% | $4.01 (+0.75%) |
Oct 14, 2026 12d ago | 8-K | $4.10 $4.03 | ▼ −1.71% | ▼ −1.99% | $4.01 (−2.20%) |
Oct 12, 2026 14d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $4.01 (−8.03%) |
Oct 7, 2026 18d ago | SC 13G/A | $4.55 $4.50 | ▲ +1.10% | ▲ +1.70% | $4.01 (+11.87%) |
Oct 2, 2026 24d ago | DEF 14A | $4.56 $4.72 | ▲ +3.62% | ▲ +3.07% | $4.01 (−11.96%) |
Sep 28, 2026 28d ago | EFFECT | $5.26 $4.88 | ▲ +7.22% | ▲ +7.04% | $4.01 (+23.76%) |
Sep 22, 2026 4w ago | Press Release | $7.01 $6.75 | ▼ −3.71% | ▼ −2.99% | $4.01 (−42.80%) |
Sep 18, 2026 5w ago | S-3 | $6.90 $7.01 | ▼ −1.59% | ▼ −1.61% | $4.01 (+41.88%) |
Sep 1, 2026 7w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $4.01 (−40.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers